Abstract:Background: Solid tumors need new blood vessels to feed and nourish them as well as to allow tumor cells to escape into the circulation and lodge in other organs, which is termed "angiogenesis." Some tumor cells within solid tumors can overexpress integrins alpha(v)beta(3) and alpha(v)beta(5), which can specifically recognize the peptide motif Arg-Gly-Asp (RGD). Thus, the targeting of RGD-modified micelles to tumor vasculature is a promising strategy for tumor-targeting treatment.Methods: RGD peptide (GSSSGRGDSPA) was coupled to poly(ethylene glycol)-modified stearic acid-grafted chitosan (PEG-CS-SA) micelles via chemical reaction in the presence of N,N'-Disuccinimidyl carbonate. The critical micelle concentration of the polymeric micelles was determined by measuring the fluorescence intensity of pyrene as a fluorescent probe. The micelle size, size distribution, and zeta potential were measured by light scattering and electrophoretic mobility. Doxorubicin (DOX) was chosen as a model anticancer drug to investigate the drug entrapment efficiency, in vitro drug-release profile, and in vitro antitumor activities of drug-loaded RGD-PEG-CS-SA micelles in cells that overexpress integrins (alpha(v)beta(3) and alpha(v)beta(5)) integrin-deficient cells.Results: Using DOX as a model drug, the drug encapsulation efficiency could reach 90%, and the in vitro drug-release profiles suggested that the micelles could be used as a controlled-release carrier for the hydrophobic drug. Qualitative and quantitative analysis of cellular uptake indicated that RGD-modified micelles could significantly increase the DOX concentration in integrin-overexpressing human hepatocellular carcinoma cell line (BEL-7402), but not in human epithelial carcinoma cell line (Hela). The competitive cellular-uptake test showed that the cellular uptake of RGD-modified micelles in BEL-7402 cells was significantly inhibited in the presence of excess free RGD peptides. In vitro cytotoxicity tests demonstrated DOX-loaded RGD-modified micelles could specifically enhance the cytotoxicity against BEL-7402 compared with DOX-loaded PEG-CS-SA and doxorubicin hydrochlorate.Conclusion: This study suggests that RGD-modified PEG-CS-SA micelles are promising drug carriers for integrin-overexpressing tumor active targeting therapy.

Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy:In vitro andin vivo

Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.

Enhanced Intracellular Uptake of Sterically Stabilized Liposomal Doxorubicin in Vitro Resulting in Improved Antitumor Activity in Vivo

[Preparation of Doxorubicin-Loaded Stealth Liposomes Modified with RGD Mimetic and Cellular Association in Vitro].

[Cellular Toxicity and Anti-Tumor Efficacy of Irgd Modified Doxorubixin Loaded Sterically Stabilized Liposomes].

Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.

The Antitumor Activity of a Doxorubicin Loaded, Irgd-Modified Sterically-Stabilized Liposome on B16-F10 Melanoma Cells: in Vitro and in Vivo Evaluation

Integrin αvβ3-targeted liposomal drug delivery system for enhanced lung cancer therapy

A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma

In vitro characterization of two new doxorubicin liposomes modified with argine-glycine-aspartic acid tripeptide or glycine-argine-glycine-aspartic acid-serine pentapeptide

Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo

cRGD-functionalized reduction-sensitive shell-sheddable biodegradable micelles mediate enhanced doxorubicin delivery to human glioma xenografts in vivo

Coadministration of Oligomeric Hyaluronic Acid-Modified Liposomes with Tumor-Penetrating Peptide-iRGD Enhances the Antitumor Efficacy of Doxorubicin Against Melanoma.

RGD Peptide-Mediated Chitosan-Based Polymeric Micelles Targeting Delivery for Integrin-Overexpressing Tumor Cells.

Targeted Sustained Delivery of Antineoplastic Agent with Multicomponent Polylactide Stereocomplex Micelle.

RGD(Arg-Gly-Asp) Internalized Docetaxel-Loaded Ph Sensitive Liposomes: Preparation, Characterization and Antitumor Efficacy in Vivo and in Vitro.

Stable Peptides Mediated Glioma Targeting Drug Delivery

Novel, nano-sized, liposome-encapsulated polyamidoamine dendrimer derivatives facilitate tumour targeting by overcoming the polyethylene glycol dilemma and integrin saturation obstacle

Doxorubicin Loaded Liposomes for Lung Tumor Targeting: in Vivo Cell Line Study in Human Lung Cancer.

Octreotide Modified PEGylated Liposomes Improved the Anticancer Efficacy of Doxorubicin in Somatostatin Receptor II Positive Tumor Model

In Vivo Biodistribution and Anti-Tumor Efficacy Evaluation of Doxorubicin and Paclitaxel-Loaded Pluronic Micelles Decorated with c(RGDyK) Peptide